News
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Pharmaceutical Technology on MSN9h
Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed
A trial investigating the ability of Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback